论文部分内容阅读
目的 :观察胺碘酮联合美托洛尔治疗冠心病合并心律失常的临床效果。方法 :将2015年6月~2016年4月在我院就诊的冠心病合并心律失常患者121例,随机分为对照组60例和治疗组61例,对照组患者口服胺碘酮片200mg/次,3次/d;联合治疗组给予胺碘酮片和美托洛尔片,起始剂量为口服12.5mg/次,2次/d,随后对两组临床资料进行回顾性分析。结果 :治疗组总有效率为90.1%,高于对照组的70.0%,差异有统计学意义;治疗后两组患者心率[(71.7±8.7)、(63.6±7.3)次/min]和QTd[(49.7±15.3)、(42.5±15.6)ms]均明显减少,与治疗前相比差异有统计学意义,且治疗组水平低于对照组,差异有统计学意义;治疗组患者的室性早搏次数[(1832.3±532.6)次]、房性早搏[(359.3±177.6)次]和交界性早搏次数[(433.1±163.2)次]与对照组比较,差异均有统计学意义。结论 :美托洛尔联合胺碘酮治疗冠心病并发心律失常效果优于单药治疗,建议临床推广。
Objective: To observe the clinical effect of amiodarone combined with metoprolol in the treatment of coronary heart disease complicated with arrhythmia. Methods: From June 2015 to April 2016, 121 patients with coronary heart disease and arrhythmia admitted to our hospital were randomly divided into control group (60 cases) and treatment group (61 cases). Patients in the control group received oral amiodarone 200mg , 3 times / d. Amiodarone tablets and metoprolol tablets were given to the combined treatment group. The initial dose was 12.5mg / time, twice a day. The clinical data of two groups were retrospectively analyzed. Results: The total effective rate of the treatment group was 90.1%, which was higher than that of the control group (70.0%), the difference was statistically significant. After treatment, heart rate (71.7 ± 8.7, 63.6 ± 7.3) / QTd (49.7 ± 15.3) and (42.5 ± 15.6) ms, respectively, which were significantly lower than those before treatment, and the difference between the two groups was statistically significant (1832.3 ± 532.6), atrial premature beats (359.3 ± 177.6) and the number of borderline premature beats (433.1 ± 163.2), compared with the control group, the differences were statistically significant. Conclusion: Metoprolol combined with amiodarone in the treatment of coronary heart disease complicated with arrhythmia is better than monotherapy, it is recommended for clinical promotion.